Skip to main content

Table 2 Tumour response

From: Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

  Patients, n(%)
Response according to irRC Aged > 70 years (n = 188) Aged ≥ 80 years (n = 26) Aged ≤ 70 years (n = 645)
irCR 4 (2) 0 (0) 25 (4)
irPR 24 (13) 1 (4) 58 (9)
irSD 44 (23) 7 (27) 131 (20)
irPD 116 (62) 18 (69) 431 (67)
irBORR 28 (15) 1 (4) 83 (13)
irDCR 72 (38) 8 (31) 214 (33)
  1. [Note to authors: summarised these data as a table and added data for patients ≥80 years].
  2. irBORR, immune-related best overall response rate; irCR, immune-related complete response; irDCR, immune-related disease control rate; irPD, immune-related progressive disease; irPR, immune-related partial response; irRC, immune-related response criteria; irSD, immune-related stable disease.